{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:41:09Z","timestamp":1761716469805},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,2,15]],"date-time":"2008-02-15T00:00:00Z","timestamp":1203033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s00520-008-0409-1","type":"journal-article","created":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T09:53:47Z","timestamp":1202982827000},"page":"557-566","source":"Crossref","is-referenced-by-count":68,"title":["Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib"],"prefix":"10.1007","volume":"16","author":[{"given":"S. E.","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. P.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,15]]},"reference":[{"issue":"18S","key":"409_CR1","first-page":"3542","volume":"25","author":"A Azad","year":"2007","unstructured":"Azad A, Annunziata C, Barrett T, Chen C, Steinberg S, Kwitkowski VE, McNally D, Kotz H, Minasian L, Kohn EC (2007) Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 25(18S):3542","journal-title":"J Clin Oncol, ASCO Annual Meeting Proceedings Part I"},{"key":"409_CR2","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1200\/JCO.2007.10.8688","volume":"25","author":"Y Bang","year":"2007","unstructured":"Bang Y, Kang Y, Kang W, Boku N, Chung H, Lanzalone S, Lechuga MJ, Sherman L, Chao R, Sobrero A (2007) Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. J Clin Oncol 25:4603","journal-title":"J Clin Oncol"},{"key":"409_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00001813-200603000-00015","volume":"17","author":"CL Bello","year":"2006","unstructured":"Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17:353\u2013358","journal-title":"Anticancer Drugs"},{"key":"409_CR4","doi-asserted-by":"crossref","unstructured":"Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI, (2007) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol DOI 10.1016\/j.euroro.2007.11.037 , Nov 26 [Epub ahead of print]","DOI":"10.1016\/j.eururo.2007.11.037"},{"key":"409_CR5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1096\/fj.00-0368com","volume":"15","author":"NV Botchkareva","year":"2001","unstructured":"Botchkareva NV, Khlgatian M, Longley BJ, Botchkarev VA, Gilchrest BA (2001) SCF\/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. Faseb J 15:645\u2013658","journal-title":"Faseb J"},{"key":"409_CR6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1468-3083.2006.01981.x","volume":"21","author":"V Brazzelli","year":"2007","unstructured":"Brazzelli V, Prestinari F, Barbagallo T, Rona C, Orlandi E, Passamonti F, Locatelli F, Zecca M, Villani S, Borroni G (2007) A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol 21:384\u2013387","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"409_CR7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"issue":"2","key":"409_CR8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","volume":"47","author":"D Chu","year":"2007","unstructured":"Chu D, Lacouture ME, Fillos T, Wu S (2007) Risk of hand\u2013foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47(2):176\u2013186","journal-title":"Acta Oncol"},{"key":"409_CR9","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.1200\/jco.2007.25.18_suppl.15532","volume":"25","author":"MM Cooney","year":"2007","unstructured":"Cooney MM, Garcia J, Brell J, Dreicer R, Beatty K, Mekhail T, Bukowski R, Zwiebel J, Remick SC, Rini BI (2007) A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol 25:15532","journal-title":"J Clin Oncol"},{"key":"409_CR10","first-page":"296","volume":"2","author":"J Dancey","year":"2003","unstructured":"Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev 2:296\u2013313","journal-title":"Nat Rev"},{"key":"409_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SMJ.0b013e31802f01a9","volume":"100","author":"CA Dasanu","year":"2007","unstructured":"Dasanu CA, Alexandrescu DT, Dutcher J (2007) Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J 100:328\u2013330","journal-title":"South Med J"},{"key":"409_CR12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329\u20131338","journal-title":"Lancet"},{"key":"409_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.aje.a117247","volume":"140","author":"A Donner","year":"1994","unstructured":"Donner A, Klar N (1994) Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol 140:279\u2013289","journal-title":"Am J Epidemiol"},{"key":"409_CR14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","volume":"18","author":"R Erber","year":"2004","unstructured":"Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18:338\u2013340","journal-title":"Faseb J"},{"key":"409_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335","journal-title":"J Clin Oncol"},{"key":"409_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2006.07.7677","volume":"25","author":"DR Feldman","year":"2007","unstructured":"Feldman DR, Kondagunta GV, Ronnen EA, Fischer P, Chang R, Baum M, Ginsberg MS, Ishill N, Patil S, Motzer RJ (2007) Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 25:1","journal-title":"J Clin Oncol"},{"key":"409_CR17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","volume":"105","author":"W Fiedler","year":"2005","unstructured":"Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105:986\u2013993","journal-title":"Blood"},{"key":"409_CR18","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/jco.2007.25.18_suppl.5080","volume":"25","author":"DJ Gallagher","year":"2007","unstructured":"Gallagher DJ, Milowsky MI, Gerst SR, Iasonos A, Riches J, Boyle MG, Bajorin DF (2007) Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol 25:5080","journal-title":"J Clin Oncol"},{"key":"409_CR19","doi-asserted-by":"crossref","first-page":"10015","DOI":"10.1200\/JCO.2006.10.4125","volume":"25","author":"S George","year":"2007","unstructured":"George S, Blay JY, Casali PG, Cesne AL, Morgan JA, Pokela J, Quigley MT, Tassell V, Baum CM, Demetri GD (2007) Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. J Clin Oncol 25:10015","journal-title":"J Clin Oncol"},{"key":"409_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2006.07.7677","volume":"25","author":"ME Gore","year":"2007","unstructured":"Gore ME, Porta C, Ourdard S, Bjamason G, Castellano D, Szczylik C, Mainwaring PN, Schoffski P, Rini BI, Bulkowski RM (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 25:1","journal-title":"J Clin Oncol"},{"key":"409_CR21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2340\/0001555576353356","volume":"76","author":"I Hagemann","year":"1996","unstructured":"Hagemann I, Proksch E (1996) Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 76:353\u2013356","journal-title":"Acta Derm Venereol"},{"key":"409_CR22","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/jco.2007.25.18_suppl.5101","volume":"25","author":"GV Kondagunta","year":"2007","unstructured":"Kondagunta GV, Hudes GR, Figlin R, Wilding G, Hariharan S, Kempin SN, Fayyad R, Hoosen S, Motzer RJ (2007) Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): results of a dose-finding study. J Clin Oncol 25:5101","journal-title":"J Clin Oncol"},{"key":"409_CR23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2165\/00128071-200304110-00005","volume":"4","author":"M Loden","year":"2003","unstructured":"Loden M (2003) Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 4:771\u2013788","journal-title":"Am J Clin Dermatol"},{"key":"409_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008390-199510000-00002","volume":"5","author":"D Luo","year":"1995","unstructured":"Luo D, Chen H, Searles G, Jimbow K (1995) Coordinated mRNA expression of c-Kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by Kit\/SCF-R. Melanoma Res 5:303\u2013309","journal-title":"Melanoma Res"},{"key":"409_CR25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"409_CR26","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516\u20132524","journal-title":"JAMA"},{"key":"409_CR27","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1200\/JCO.2007.13.3751","volume":"25","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, Bjarnason GA, Kim ST, Chen I, Michaelson D (2007) Sunitinib versus interferon-alfa (IFN-\u03b1) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 25:5024","journal-title":"J Clin Oncol"},{"key":"409_CR28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"409_CR29","first-page":"753","volume":"26","author":"ME Mrozek-Orlowski","year":"1999","unstructured":"Mrozek-Orlowski ME, Frye DK, Sanborn HM (1999) Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 26:753\u2013762","journal-title":"Oncol Nurs Forum"},{"key":"409_CR30","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"key":"409_CR31","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1200\/jco.2007.25.18_suppl.10022","volume":"25","author":"P Reichardt","year":"2007","unstructured":"Reichardt P, Yang YK, Ruka W, Seddon B, Baum CM, Demetri GD (2007) Subpopulation analyses in a worldwide treatment-use of sunitinib (SU) in GIST patients (pts) with resistance intolerance to prior imatinib (IM) therapy. J Clin Oncol 25:10022","journal-title":"J Clin Oncol"},{"key":"409_CR32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","volume":"18","author":"O Rixe","year":"2007","unstructured":"Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of sunitinib activity. Ann Oncol 18:1117","journal-title":"Ann Oncol"},{"key":"409_CR33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-143-4-200508160-00021","volume":"143","author":"C Robert","year":"2005","unstructured":"Robert C, Faivre S, Raymond E, Armand JP, Escudier B (2005) Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143:313\u2013314","journal-title":"Ann Intern Med"},{"key":"409_CR34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491\u2013500","journal-title":"Lancet Oncol"},{"key":"409_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","volume":"12","author":"EP Rock","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, Dagher R, Justice R, Pazdur R (2007) Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12:107\u2013113","journal-title":"Oncologist"},{"key":"409_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"409_CR37","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1200\/jco.2007.25.18_suppl.5040","volume":"25","author":"S Srinivas","year":"2007","unstructured":"Srinivas S, Roigas J, Gillessen S, Hamenberg U, Mulder PHD, Fountzilas G, Vogelzang N, Peschel C, Flodgren P, Escudier B (2007) Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results. J Clin Oncol 25:5040","journal-title":"J Clin Oncol"},{"key":"409_CR38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426\u2013437","journal-title":"Oncologist"},{"key":"409_CR39","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/jco.2007.25.18_suppl.3592","volume":"25","author":"C Sweeney","year":"2007","unstructured":"Sweeney C, Verschraegen C, Chiorean C, Lee F, Jones S, Tye L, Bello A, Chao R, Burris H (2007) A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 25:3592","journal-title":"J Clin Oncol"},{"key":"409_CR40","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1200\/JCO.2006.08.6868","volume":"24","author":"KY Tsai","year":"2006","unstructured":"Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW (2006) Hand\u2013foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 24:5786\u20135788","journal-title":"J Clin Oncol"},{"key":"409_CR41","first-page":"5","volume":"3","author":"LS Wood","year":"2006","unstructured":"Wood LS (2006) Nursing management: managing the side effects of sorafenib and sunitinib. Community Oncol 3:5","journal-title":"Community Oncol"},{"key":"409_CR42","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1200\/jco.2007.25.18_suppl.4637","volume":"25","author":"AX Zhu","year":"2007","unstructured":"Zhu AX, Sahani DV, Tomaso ED, Duda D, Sindhwani V, Yoon SS, Blaszkowsky LS, Clark JW, Ryan DP, Jain RK (2007) A phase II study of sunitinib in patients with advanced hepatocellular cancer. J Clin Oncol 25:4637","journal-title":"J Clin Oncol"},{"key":"409_CR43","unstructured":"Zurita AJ, Shore N, Kozloff M, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis C, (2007) Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHPRC). In 2007 ASCO Prostate Cancer Symposium. Abstract No. 230"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-008-0409-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0409-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T10:04:49Z","timestamp":1708596289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-008-0409-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,15]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s00520-008-0409-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,15]]}}}